Adaptimmune, GSK expand TCR deal for NY-ESO-1

Adaptimmune Therapeutics plc (NASDAQ:ADAP) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expanded a deal under which the companies are co-developing an autologous T cell receptor ( TCR) therapy targeting cancer/testis antigen 1B ( CTAG1B; NY-ESO-1).

Under the expanded deal, Adaptimmune will start a pivotal trial of the NY-ESO-1 TCR therapy (GSK3377794) to treat synovial sarcoma by YE16, and will explore starting pivotal trials in myxoid round cell liposarcoma. Additionally, the companies now may start up to eight proof-of-principle studies of the NY-ESO-1 therapy in combination with other therapies, including checkpoint inhibitors. ...